TDP-43 Proteinopathy Investment Landscape

📖 Wiki Page

investment940 wordssynced 2026-04-02

TDP-43 Proteinopathy Investment

Overview

This page summarizes trial-derived R&D investment signals for TDP-43 proteinopathy therapeutics, primarily focused on [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) and [Frontotemporal Dementia (FTD)](/diseases/frontotemporal-dementia), the two conditions where TDP-43 pathology is most prominent. TDP-43 (TAR DNA-binding protein 43) aggregates are found in ~95% of ALS cases and ~50% of FTD cases [@neumann2006][@arai2006].

Portfolio Metrics

| Metric | ALS | FTD |
|---|---|---:|
| Total tracked trials | 750 | 113 |
| Active trials | 189 (25.2%) | 31 (27.4%) |
| Completed trials | 351 (46.8%) | 41 (36.3%) |
| Late-stage (Phase 3/4) | 70 (9.3%) | 6 (5.3%) |
| Phase 1/2 programs | 275 (36.7%) | 18 (15.9%) |

Combined TDP-43 Pipeline: 863 trials across ALS and FTD

Therapeutic Approach Categories

Small Molecule Approaches

| Approach | ALS Trials | FTD Trials | Status |
|---|---|---|---|
| Mitochondrial modulators | 525 | Limited | Most advanced |
| Genetic targeting | 52 | 12 | Growing |
| Neuroinflammation targets | 10 | 8 | Early stage |
| Neurotransmitter modulation | 5 | 3 | Established |
| Growth factor therapy | 6 | 2 | Early stage |

Gene Therapy and Antibody Approaches

...

TDP-43 Proteinopathy Investment

Overview

Portfolio Metrics

Combined TDP-43 Pipeline: 863 trials across ALS and FTD

Therapeutic Approach Categories

Small Molecule Approaches

Gene Therapy and Antibody Approaches

The TDP-43 proteinopathy field is increasingly focusing on:

Antisense oligonucleotides (ASOs): Targeting TARDBP gene expression
Gene replacement: Delivering functional TDP-43
Antibody therapies: Anti-TDP-43 monoclonal antibodies
Small molecules: Aggregation inhibitors, [autophagy](/entities/autophagy) enhancers

Trial Status Distribution

ALS Trial Status

| Category | Trial Count | Share |
|---|---|---:|
| Active/Recruiting | 189 | 25.2% |
| Recruiting | 122 | 16.3% |
| Not Yet Recruiting | 27 | 3.6% |
| Active Not Recruiting | 34 | 4.5% |
| Enrolling By Invitation | 6 | 0.8% |
| Historical | 561 | 74.8% |
| Completed | 351 | 46.8% |
| Terminated | 66 | 8.8% |
| Withdrawn | 28 | 3.7% |
| Unknown | 100 | 13.3% |

FTD Trial Status

| Category | Trial Count | Share |
|---|---|---:|
| Active/Recruiting | 31 | 27.4% |
| Historical | 82 | 72.6% |
| Completed | 41 | 36.3% |
| Terminated | 12 | 10.6% |
| Withdrawn | 8 | 7.1% |

Mechanism Cluster Distribution

Mermaid diagram (expand to render)

| Mechanism Cluster | ALS Trials | Primary Focus |
|---|---|---|
| Mitochondrial biology | 525 (70.0%) | Energy metabolism, oxidative stress |
| Genetic / gene-targeted | 52 (6.9%) | SOD1, [C9orf72](/entities/c9orf72), TARDBP |
| Amyloid biology | 14 (1.9%) | TDP-43 aggregation |
| Neuroinflammation | 10 (1.3%) | Microglial modulation |
| Synaptic function | 7 (0.9%) | Neuroprotection |
| Growth factor | 6 (0.8%) | Neuronal support |

Key Insight: Mitochondrial dysfunction dominates the ALS pipeline (70%), reflecting the central role of energy failure in TDP-43 proteinopathy [@cozzolino2019].

Top Academic Sponsors (ALS)

| Sponsor | Trial Count |
|---|---:|
| Peking University Third Hospital | 18 |
| Assistance Publique - Hopitaux de Paris | 17 |
| Massachusetts General Hospital | 13 |
| University of Michigan | 11 |
| Drexel University College of Medicine | 10 |
| Mayo Clinic | 9 |
| Johns Hopkins University | 8 |
| University of Miami | 8 |

Pharmaceutical Companies

| Company | ALS Trials | Notable Programs |
|---|---|---|
| Biogen | 8 | ASO therapies, C9orf72 |
| Cytokinetics | 8 | Tirasemtiv, reldesemtiv |
| Knopp Biosciences | 9 | KD7000 series |
| Amylyx Pharmaceuticals | 5 | AMX0035 (approved) |
| Neuralstem | 4 | Cell therapy |
| Roche | 3 | Genentech collaboration |

Gap Analysis

Underexplored Areas

TDP-43 Aggregation Inhibitors: Few trials specifically targeting TDP-43 aggregation

FTD-Specific Programs: Only 113 trials vs 750 for ALS — significant imbalance

Biomarker-Driven Trials: Limited incorporation of TDP-43 biomarkers

Combination Therapies: Almost no combination approach trials

Prevention Trials: Few trials targeting pre-symptomatic carriers

Strategic Opportunities

TDP-43-Targeted ASOs: Direct targeting of TARDBP expression

C9orf72 Programs: Expansion of repeat expansion-targeted approaches

Autophagy Enhancement: Clearing TDP-43 aggregates

FTD Pipeline Development: Significant unmet need and opportunity

Biomarker Integration: TDP-43 in CSF/blood as stratification marker

[TDP-43 Proteinopathy - Mechanism Page](/mechanisms/tdp-43-proteinopathy)
[ALS Investment Landscape](/investment/als)
[FTD Investment Landscape](/investment/ftd)
[TDP-43 Protein - Protein Page](/proteins/tdp-43-protein)
[TARDBP Gene - Gene Page](/genes/tardbp)
[LATE Disease - Limbic-Predominant Age-Related TDP-43 Encephalopathy](/diseases/late)

External Links

[ClinicalTrials.gov - ALS Trials](https://clinicaltrials.gov/search?cond=amyotrophic+lateral+sclerosis)
[ClinicalTrials.gov - FTD Trials](https://clinicaltrials.gov/search?cond=frontotemporal+dementia)
[PubMed - TDP-43 Therapeutics](https://pubmed.ncbi.nlm.nih.gov/?term=TDP-43+therapeutics+ALS)

Clinical Trials

For current clinical trials targeting TDP-43 pathology in ALS and FTD, see:

[Clinical Trials Index](/clinical-trials)

References

[Neumann M, et al, "Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis." Science (2006)](https://pubmed.ncbi.nlm.nih.gov/17023659/)

[Arai T, et al, "TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis." Biochem Biophys Res Commun (2006)](https://pubmed.ncbi.nlm.nih.gov/17084815/)

[Cozzolino M, et al, "Mitochondrial dysfunction in amyotrophic lateral sclerosis: the contribution of the mitochondrial quality control." Cell Death Dis (2019)](https://pubmed.ncbi.nlm.nih.gov/31043575/)

[Taylor JP, et al, "Decoding ALS: from genes to mechanism." Nature (2016)](https://pubmed.ncbi.nlm.nih.gov/27806378/)

[Rascovsky K, et al, "Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia." Brain (2011)](https://pubmed.ncbi.nlm.nih.gov/21810890/)

📖 View canonical wiki page →

TDP-43 Proteinopathy Investment Landscape

TDP-43 Proteinopathy Investment

Overview

Portfolio Metrics

Therapeutic Approach Categories

Small Molecule Approaches

Gene Therapy and Antibody Approaches

TDP-43 Proteinopathy Investment

Overview

Portfolio Metrics

Therapeutic Approach Categories

Small Molecule Approaches

Gene Therapy and Antibody Approaches

Trial Status Distribution

ALS Trial Status

FTD Trial Status

Mechanism Cluster Distribution

Sponsor Landscape

Top Academic Sponsors (ALS)

Pharmaceutical Companies

Gap Analysis

Underexplored Areas

Strategic Opportunities

Cross-Links to Related Pages

See Also

External Links

Clinical Trials

References